News About: Pharm. Industry
Is Cervarix building up a cause for the NIP?
The company which owns ‘Cervarix,’ a uterine cervix cancer vaccine, announced data of an cost-benefit analysis that the drug is more cost-effective than its competing product, ‘Gardasil.’ In the circumstance where it ...
Which company will acquire ‘Mercilon’ this November?
The whereabouts of ‘Mercilon,’ a Bayer’s oral contraceptive, which will be decided within this month, has attracted attention.
As pointed out for the Substantial Lessening of Competition by the Fair Trade Commission(...
Hanmi Pharm signed an license agreement of new bio-drug with JanssenHanmi Pharm(CEO Kwan-soon Lee) announced a license agreement to develop and commercialize HM12525A (LAPSGLP/GCG), a self-developed oxyntomodulin-based diabetes and obesity treat...
|
Hanmi Pharm closer to Celltrion in market capitalizationHanmi Pharm has exceeded KRW 8 trillion in market capitalization from a series of technology exports.
It has gotten closer by KRW 200 billion to the leading market capitalizati...
|
Hanmi Pharm, history maker, to record most pharmaceutical manufacturing outputIt was known among the top 20 domestic pharmaceutical companies Hanmi Pharm recorded the highest pharmaceutical manufacturing output last year.
According to the analysis result...
|
Sanofi chose Hanmi against threat of Lantus patent expirationThe reason why Sanofi established a technology transfer contract worth of KRW 5 trillion with Hanmi Pharm is analyzed as the company considered the patent expiration of ‘Lantus,...
|
Remarkable ‘clinical studies’ of domestic pharmaceutical companies focusing on future-oriented treatments
Domestic companies have always had desire towards new drugs. However, the problem is it takes so much more time and money to invest in new drugs than generics.
Recently, however, domestic pharmaceutical companies hav...
Hanmi established license contract of diabetes treatments with Sanofi for EUR 400 millionHanmi Pharm announced on the 5th that Sanofi established a license contract for the Quantum Project, a portfolio of long-acting diabetes new drugs, which has been developed by H...
|
“The belief of Hanmi Pharm President Sung-gi Lim to develop new drugs has been glowing”The belief of President Sung-gi Lim of Hanmi Pharm, which has focused on R&D investment for the past 15 years, has been glowing in the global pharmaceutical market.
On the 5th,...
|
Samsung Biologics, “We will become the top CSO by 2020”Samsung Biologics which takes change in the Samsung Group’s biopharmaceutical manufacturing business announced a goal to become the top in the biopharmaceutical ‘Contract Manufa...
|
